LOGIN
ID
PW
MemberShip
2023-12-07 13:12
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Policy
Yuhan¡¯s Leclaza passes DREC review for 1st-line NSCLC
by
Lee, Tak-Sun
Oct 16, 2023 05:24am
Yuhan Corp¡¯s application to extend coverage for its 3rd-generation EGFR TKI non-small-cell lung cancer treatment Leclaza (lasertinib)' as a first-line treatment is making rapid progress. After passing the Health Insurance Review and Assessment Service review, all that remains is drug price negotiations with the National Health Insurance
Policy
Regkirona approval is for the Moon care to build up records
by
Lee, Jeong-Hwan
Oct 13, 2023 05:30am
People Power Party lawmaker Lee Jong-seong pointed out the Moon Jae-in government's budget support for Celltrion's COVID-19 treatment Regkirona as a problem. Rep. Lee Jong-seong criticized the approval of Regkirona, saying it lacked proper verification of effectiveness in order to build on the previous government's legacy of the K vaccine. O
Policy
NA Rep Kang ¡®Increase gov't support to treat breast cancer'
by
Lee, Jeong-Hwan
Oct 13, 2023 05:29am
It has been pointed out that the government should strengthen economic support for innovative new drugs that treat severe diseases to improve the treatment rate of breast cancer patients. The number of female cancer patients is significantly higher than that of male cancer patients in the same age group, and the number of breast cancer
Policy
The fate of the drugs identified in the inspeciton inspectio
by
Lee, Tak-Sun
Oct 13, 2023 05:29am
Specifically, they are breast cancer treatment Enhertu, Parkinson's disease treatment Madopar, and other immunotherapy drugs. Enhertu was mentioned by People Power Party lawmaker Kang Ki-yoon. He said that the number of female cancer patients is rapidly increasing and ordered coverage of expensive innovative treatments. At this point, Enh
Policy
Reimb extensions for Keytruda to be rediscussed later
by
Lee, Tak-Sun
Oct 13, 2023 05:29am
MSD Korea's immunotherapy drug 'Keytruda (pembrolizumab)', which applied for a large-scale reimbursement extension, was unable to pass the first hurdle and was determined in need of rediscussions. The authorities plan to first receive the pharmaceutical company's financial sharing plan and then decide whether to set a reimbursement stand
Policy
Overseas drug price comparison plan to be announced
by
Lee, Tak-Sun
Oct 12, 2023 05:37am
The final plan will likely be finalized after gathering opinions from the pharmaceutical industry. It is expected that a plan to reevaluate overseas drug prices will be revealed around the end of the year. Health authorities plan to prepare a reevaluation plan by the end of the year and then proceed with it starting next year. According to t
Policy
AD drug Dupixent¡¯s fails 1st negotiations for RSA renewal
by
Lee, Tak-Sun
Oct 12, 2023 05:37am
The first round of negotiations to renew the risk-sharing agreement (RSA) contract for the severe atopic dermatitis treatment ¡®Dupixent (dupilumab, Sanofi)¡¯ has fallen through. The company and the National Health Insurance Service plan to discuss Dupixent¡¯s RSA renewal through additional negotiations. According to the industry on t
Policy
75% of patients who administered Kymriah is not effective
by
Lee, Jeong-Hwan
Oct 11, 2023 05:37am
More than 75% of patients who received the ultra-high-priced drug Kymriah, which costs 360 million won in one dose, did not have an improvement effect. On the 6th, Kim Young-joo, a member of the National Assembly Health and Welfare Committee (the Democratic Party, Yeongdeungpo Gap) received data from the Health Insurance Review and Assess
Policy
¡®Little progress for NIP support of 9-valent HPV vaccines'
by
Lee, Jeong-Hwan
Oct 11, 2023 05:36am
The number of patients receiving treatment for head and neck cancer and oropharyngeal cancer, both of which are caused by HPV (human papillomavirus), is on the rise. In just a decade, from 2013 to last year, the number of head and neck cancer patients increased by 41.6%, and the number of oropharyngeal cancer patients increased by 56%. In
Policy
Eisai¡¯s Jyseleca completes negotiations with NHIS for reimb
by
Lee, Tak-Sun
Oct 11, 2023 05:36am
Eisai Korea has completed negotiations with the National Health Insurance Service for its JAK inhibitor ¡®Jyseleca Tab (filgotinib).¡¯ As a result, Jyseleca is now on the verge of being listed for reimbursement in Korea. This drug is the 5th JAK inhibitor introduced to Korea. It has a mechanism of action that selectively inhibits JAK1, t
1
2
3
4
5
6
7
8
9
10
>